Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026)
Atea Pharmaceuticals (AVIR) posted quarterly Income from Continuing Operations of 45440000.0 for Q1 2026, down 32.59% year-over-year from 67404764.54 in Q1 2025, and down 1.28% quarter-over-quarter from 44867000.0 in Q4 2025.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 45440000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 32.59% year-over-year to 45440000.0; the TTM figure through Mar 2026 stood at 169517000.0 (down 21.53% YoY), while the FY2025 annual figure was 158349000.0, up 5.96% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 45440000.0, down from 44867000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8066000.0 in Q3 2022, with the low at 63169000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 35467000.0 (2023), against an average of 36708176.47.
- Peak annual rise in Income from Continuing Operations reached 71.39% in 2022, while the deepest fall reached 2136.06% in 2022.
- Atea Pharmaceuticals' Income from Continuing Operations stood at 34431000.0 in 2022, then fell by 13.75% to 39164000.0 in 2023, then gained by 14.35% to 33543000.0 in 2024, then sank by 33.76% to 44867000.0 in 2025, then retreated by 1.28% to 45440000.0 in 2026.
- Business Quant data shows AVIR's Income from Continuing Operations at 45440000.0 in Q1 2026, 44867000.0 in Q4 2025, and 42049000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Atea Pharmaceuticals | 468.30 Mn | 468.30 Mn | - | -32.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.93 Mn |
| Mar 31, 2026 | -45.44 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Sep 30, 2025 | -42.05 Mn |
| Jun 30, 2025 | -37.16 Mn |
| Mar 31, 2025 | -34.27 Mn |
| Dec 31, 2024 | -33.54 Mn |
| Sep 30, 2024 | -31.15 Mn |
| Jun 30, 2024 | -40.52 Mn |
| Mar 31, 2024 | -63.17 Mn |
| Dec 31, 2023 | -39.16 Mn |
| Sep 30, 2023 | -33.14 Mn |
| Jun 30, 2023 | -28.18 Mn |
| Mar 31, 2023 | -35.47 Mn |
| Dec 31, 2022 | -34.43 Mn |
| Sep 30, 2022 | -8.07 Mn |
| Jun 30, 2022 | -31.34 Mn |
| Mar 31, 2022 | -42.08 Mn |
| Dec 31, 2021 | 117.13 Mn |
| Sep 30, 2021 | -28.19 Mn |